CD274 and non-small cell lung carcinoma: In real-world retrospective study involving 211 cases of stage I–IV NSCLC, the prevalence of PD-L1 TPS ≥ 1% varied from 27% to 47.4% depending on the assay, while TPS ≥ 50% reached only 12.8% [42].